Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in mid-2024.
Similar Posts
Holiday shopping: These stocks in the retail sector are seen as value plays
Post Content Post Views: 70
BMO USD Cash Management ETF declares $0.135 dividend
Post Content Post Views: 78
Taiwan says Australian warship sailed through Taiwan Strait
Post Content Post Views: 66
Evergrande creditor group supports maintaining operations, not bankruptcy-SCMP
Post Content Post Views: 78
Exxon Mobil CEO urges COP28 to focus on reducing emissions — not phasing out fossil fuels
Exxon Mobil CEO Darren Woods on Saturday said the “problem statement” that countries need to focus on at the COP28 climate summit is reducing emissions. Post Views: 75
US consumers’ inflation expectations rise for 2nd month – UMich
Post Content Post Views: 83